Traws Pharma, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Traws Pharma, Inc. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $9.24M, a 203.85% increase year-over-year.
- Traws Pharma, Inc. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $1.80M, a 1464.35% increase year-over-year.
- Traws Pharma, Inc. stock issued during period, value, new issues for the quarter ending 2025-12-31 was $1.93M.
- Traws Pharma, Inc. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $113.00K.
- Traws Pharma, Inc. stock issued during period, value, new issues for fiscal 2025 was $5.20M.
- Traws Pharma, Inc. stock issued during period, value, new issues for fiscal 2021 was $55.04M, a 507.38% increase from fiscal 2020.
- Traws Pharma, Inc. stock issued during period, value, new issues for fiscal 2020 was $9.06M.
- Traws Pharma, Inc. stock issued during period, value, new issues for fiscal 2017 was $6.36M, a 510.95% increase from fiscal 2016.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $9.24M 10-Q · filed 2026-08-14 | $13.09M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $1.80M 10-Q · filed 2026-05-15 | $6.89M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $1.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $5.20M 10-K · filed 2026-04-15 |
| 2025-09-30 | $113.00K 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $3.04M 10-Q · filed 2026-08-14 | |
| 2025-03-31 | $115.00K 10-Q · filed 2026-05-15 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | |
| 2024-06-30 | $427.00K 10-Q · filed 2025-08-14 | |
| 2021-12-31 | -$50.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $55.04M 10-K · filed 2023-03-30 |
| 2021-09-30 | $19.94M 10-Q · filed 2022-11-14 | $55.09M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $35.15M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $35.15M 10-Q · filed 2022-05-13 | $35.15M derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $9.06M 10-K · filed 2022-03-21 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | |
| 2020-03-31 | $9.06M 10-Q · filed 2021-05-17 | |
| 2019-09-30 | $2.97M 10-Q · filed 2020-11-16 | |
| 2019-06-30 | $392.00K 10-Q · filed 2020-08-12 | |
| 2017-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $6.36M 10-K · filed 2019-04-01 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $5.32M derived: sum of 4 quarters · filed 2018-03-16 |
| 2017-06-30 | $5.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $5.32M derived: sum of 4 quarters · filed 2018-03-16 |
| 2017-03-31 | $40.00K 10-Q · filed 2017-05-15 | $38.00K derived: sum of 4 quarters · filed 2018-03-16 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $1.04M 10-K · filed 2018-03-16 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $3.69M derived: sum of 4 quarters · filed 2017-03-29 |
| 2016-06-30 | -$2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $8.39M derived: sum of 4 quarters · filed 2017-03-29 |
| 2016-03-31 | $1.04M 10-Q · filed 2016-05-11 | |
| 2015-12-31 | $2.65M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-29 | $7.46M 10-K · filed 2017-03-29 |
| 2015-09-30 | $4.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-30 | $79.81M 10-K · filed 2015-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |